StreetInsider.com News Articles

Form 8-K CDT Equity Inc. For: May 21

Thu, 28 May 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260528/26567931.html

Form 8-K CDT Equity Inc. For: May 21

Thu, 28 May 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260528/26567931.html

CDT Equity Inc. Announces Receipt of Nasdaq Deficiency Letter

Thu, 28 May 2026 16:15:00 -0400

NAPLES, Fla. and CAMBRIDGE, United Kingdom, May 28, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today announced that the Company received a written notice (“Notice”) from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) on May 21, 2026 indicating that the Company did not timely file its Quarterly Report on Form 10-Q for the three-month period ended March 31, 2026 (the “Form 10-Q”), as required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5250(c)(1) (the “Periodic Filing Requirement”). The Notice does not

CDT Equity Inc. Announces Receipt of Nasdaq Deficiency Letter

Thu, 28 May 2026 16:15:00 -0400

CDT Equity Inc. Announces Receipt of Nasdaq Deficiency Letter

Thu, 28 May 2026 16:15:00 -0400

CDT Equity Inc. Announces Receipt of Nasdaq Deficiency Letter

Thu, 28 May 2026 16:15:00 -0400

CDT receives Canadian patent for AZD5904 male infertility treatment

Wed, 27 May 2026 08:01:55 -0400

CDT Equity Inc. (NASDAQ: CDT) announced that Canada has granted a patent covering the use of AZD5904 for male infertility treatment. The approval completes patent coverage for the compound across key pharmaceutical markets globally.

The company stated that this geographical patent coverage, combined with its composition of matter application, establishes intellectual property protection for AZD5904 development as it pursues licensing and strategic partnership opportunities.

AZD5904 was originally licensed from AstraZeneca and includes clinical safety data and pre-clinical validation for male infertility applications. The compound targets an area where no approved drug therapies currently exist specifically for male infertility.

"Globally, the male infertility market

CDT Announces Canadian Patent for AZD5904 in Male Infertility

Wed, 27 May 2026 08:00:00 -0400

NAPLES, Fla. and CAMBRIDGE, United Kingdom, May 27, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today announces that the patent covering the use of AZD5904 in male infertility has now been granted in Canada, completing the approval of this patent in all key pharmaceutical target markets.

CDT believes that the extensive geographical coverage of this patent combined with its more recent composition of matter application provides a strong IP position for development of AZD5904 in male infertility as discussions continue regarding potential licensing and strategic partnering opportunities.

Originally licensed from

CDT Announces Canadian Patent for AZD5904 in Male Infertility

Wed, 27 May 2026 08:00:00 -0400

Originally licensed from

CDT Announces Canadian Patent for AZD5904 in Male Infertility

Wed, 27 May 2026 08:00:00 -0400

Originally licensed from

CDT Announces Canadian Patent for AZD5904 in Male Infertility

Wed, 27 May 2026 08:00:00 -0400

Originally licensed from

Form SCHEDULE 13G CDT Equity Inc. Filed by: Nirland Ltd

Wed, 20 May 2026 19:04:00 -0400

si-local-file:///var/storage/secattach/20260520/26529903.html

Form SCHEDULE 13G CDT Equity Inc. Filed by: Nirland Ltd

Wed, 20 May 2026 19:04:00 -0400

si-local-file:///var/storage/secattach/20260520/26529903.html

Form NT 10-Q CDT Equity Inc. For: Mar 31

Fri, 15 May 2026 16:35:00 -0400

si-local-file:///var/storage/secattach/20260515/26506611.html

Form NT 10-Q CDT Equity Inc. For: Mar 31

Fri, 15 May 2026 16:35:00 -0400

si-local-file:///var/storage/secattach/20260515/26506611.html

Form 8-K CDT Equity Inc. For: May 15

Fri, 15 May 2026 16:03:00 -0400

si-local-file:///var/storage/secattach/20260515/26504752.html

Form 8-K CDT Equity Inc. For: May 15

Fri, 15 May 2026 16:03:00 -0400

si-local-file:///var/storage/secattach/20260515/26504752.html

Form SCHEDULE 13D/A CDT Equity Inc. Filed by: Corvus Capital Ltd.

Thu, 14 May 2026 08:48:00 -0400

si-local-file:///var/storage/secattach/20260514/26490823.html

Form SCHEDULE 13D/A CDT Equity Inc. Filed by: Corvus Capital Ltd.

Thu, 14 May 2026 08:48:00 -0400

si-local-file:///var/storage/secattach/20260514/26490823.html

Form 4 CDT Equity Inc. For: Mar 24 Filed by: Regan Andrew

Thu, 14 May 2026 08:43:00 -0400

si-local-file:///var/storage/secattach/20260514/26490779.html

Form 4 CDT Equity Inc. For: Mar 24 Filed by: Regan Andrew

Thu, 14 May 2026 08:43:00 -0400

si-local-file:///var/storage/secattach/20260514/26490779.html

CDT notes Sarborg patent filing for cystic fibrosis compounds

Thu, 07 May 2026 08:30:28 -0400

CDT Equity Inc. (NASDAQ: CDT) announced that Sarborg Limited filed a Substance of Matter patent covering two compounds in the cystic fibrosis market. CDT holds a 20% stake in Sarborg.

Sarborg developed the patent using its proprietary Signature Agent and Multi-Agent platform, supported by disease databases containing 1,600 diseases and 1,700 rare diseases. The company completed the patent filing in less than three weeks, according to the announcement.

CDT stated it views the development as validation of Sarborg's platform capabilities for generating intellectual property within compressed timeframes. The company is working with Sarborg to evaluate its existing asset portfolio and identify potential

CDT Notes Sarborg Filing of Substance of Matter Patent in Cystic Fibrosis Market

Thu, 07 May 2026 08:30:00 -0400

NAPLES, Fla. and CAMBRIDGE, United Kingdom, May 07, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today notes the announcement from Sarborg Limited regarding the filing of a new Substance of Matter (SOM) patent covering two established compounds within the cystic fibrosis market.

Sarborg announced that the patent was developed using its proprietary Signature Agent and Multi-Agent platform, supported by its Sarborg 1,600 Disease Database and Sarborg 1,700 Rare Disease Database. According to Sarborg, this approach enables rapid identification of new therapeutic opportunities, including additional indications and combination strategies, with

CDT Notes Sarborg Filing of Substance of Matter Patent in Cystic Fibrosis Market

Thu, 07 May 2026 08:30:00 -0400

CDT Notes Sarborg Filing of Substance of Matter Patent in Cystic Fibrosis Market

Thu, 07 May 2026 08:30:00 -0400